{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:23:47Z","timestamp":1786994627908,"version":"build-2736575974"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,1,11]],"date-time":"2016-01-11T00:00:00Z","timestamp":1452470400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000065","name":"NINDS","doi-asserted-by":"publisher","award":["1ZIANS003038-09"],"award-info":[{"award-number":["1ZIANS003038-09"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurobiology of Disease"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.nbd.2016.01.008","type":"journal-article","created":{"date-parts":[[2016,1,11]],"date-time":"2016-01-11T12:30:58Z","timestamp":1452515458000},"page":"118-124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["CNS uptake of bortezomib is enhanced by P-glycoprotein inhibition: implications for spinal muscular atrophy"],"prefix":"10.1016","volume":"88","author":[{"given":"Emily","family":"Foran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah Y.","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan H.","family":"Nofziger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eveline S.","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth H.","family":"Fischbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barrington G.","family":"Burnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.nbd.2016.01.008_bb0005","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1158\/1078-0432.CCR-10-1950","article-title":"Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events","volume":"17","author":"Arastu-Kapur","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.nbd.2016.01.008_bb0010","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1182\/blood-2008-04-149385","article-title":"Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature","volume":"112","author":"Argyriou","year":"2008","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.nbd.2016.01.008_bb9000","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/ana.22421","article-title":"The blood-spinal cord barrier: morphology and clinical implications","volume":"70","author":"Bartanusz","year":"2011","journal-title":"Ann. Neurol."},{"issue":"5","key":"10.1016\/j.nbd.2016.01.008_bb0015","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/jcbfm.2015.19","article-title":"Approaching complete inhibition of P-glycoprotein at the human blood\u2013brain barrier: an (R)-[11c]verapamil pet study","volume":"35","author":"Bauer","year":"2015","journal-title":"J. Cereb. Blood Flow Metab."},{"issue":"8","key":"10.1016\/j.nbd.2016.01.008_bb0020","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.2967\/jnumed.112.118232","article-title":"Interaction of 11c-tariquidar and 11c-elacridar with P-glycoprotein and breast cancer resistance protein at the human blood\u2013brain barrier","volume":"54","author":"Bauer","year":"2013","journal-title":"J. Nucl. Med."},{"issue":"1","key":"10.1016\/j.nbd.2016.01.008_bb0025","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.nbd.2006.06.014","article-title":"The multidrug transporter hypothesis of drug resistance in epilepsy: proof-of-principle in a rat model of temporal lobe epilepsy","volume":"24","author":"Brandt","year":"2006","journal-title":"Neurobiol. Dis."},{"issue":"1","key":"10.1016\/j.nbd.2016.01.008_bb0030","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000235820","article-title":"Mdr1 C3435t polymorphism indicates a different outcome in advanced multiple myeloma","volume":"122","author":"Buda","year":"2009","journal-title":"Acta Haematol."},{"issue":"11","key":"10.1016\/j.nbd.2016.01.008_bb0035","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s00277-010-0992-3","article-title":"Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin","volume":"89","author":"Buda","year":"2010","journal-title":"Ann. Hematol."},{"issue":"7","key":"10.1016\/j.nbd.2016.01.008_bb0040","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/emmm.201202305","article-title":"Enhancement of Smn protein levels in a mouse model of spinal muscular atrophy using novel drug-like compounds","volume":"5","author":"Cherry","year":"2013","journal-title":"EMBO Mol. Med."},{"issue":"3","key":"10.1016\/j.nbd.2016.01.008_bb0045","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1128\/MCB.9.3.1346","article-title":"The three mouse multidrug resistance (Mdr) genes are expressed in a tissue-specific manner in normal mouse tissues","volume":"9","author":"Croop","year":"1989","journal-title":"Mol. Cell. Biol."},{"issue":"4","key":"10.1016\/j.nbd.2016.01.008_bb0050","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1055\/s-0028-1103272","article-title":"Abc transporter (P-Gp\/Abcb1, Mrp1\/Abcc1, Bcrp\/Abcg2) expression in the developing human Cns","volume":"39","author":"Daood","year":"2008","journal-title":"Neuropediatrics"},{"issue":"3","key":"10.1016\/j.nbd.2016.01.008_bb0055","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nbt.1610","article-title":"Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of Smn","volume":"28","author":"Foust","year":"2010","journal-title":"Nat. Biotechnol."},{"issue":"6B","key":"10.1016\/j.nbd.2016.01.008_bb0060","first-page":"4021","article-title":"Activity of bortezomib in adult de novo and relapsed acute myeloid leukemia","volume":"27","author":"Gil","year":"2007","journal-title":"Anticancer Res."},{"issue":"7367","key":"10.1016\/j.nbd.2016.01.008_bb0065","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nature10485","article-title":"Peripheral Smn restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model","volume":"478","author":"Hua","year":"2011","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.nbd.2016.01.008_bb0070","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/acn3.141","article-title":"Inhibiting drug efflux transporters improves efficacy of Als therapeutics","volume":"1","author":"Jablonski","year":"2014","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"14 Suppl. 11","key":"10.1016\/j.nbd.2016.01.008_bb0075","first-page":"4","article-title":"Discovery, development, and clinical applications of bortezomib","volume":"18","author":"Jung","year":"2004","journal-title":"Oncology (Williston Park)"},{"issue":"2","key":"10.1016\/j.nbd.2016.01.008_bb0080","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1021\/cn100078a","article-title":"The \"Specific\" P-glycoprotein inhibitor tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (Bcrp\/Abcg2)","volume":"2","author":"Kannan","year":"2011","journal-title":"ACS Chem. Neurosci."},{"issue":"9","key":"10.1016\/j.nbd.2016.01.008_bb0085","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1093\/hmg\/ddi130","article-title":"The role of histone acetylation in smn gene expression","volume":"14","author":"Kernochan","year":"2005","journal-title":"Hum. Mol. Genet."},{"issue":"1","key":"10.1016\/j.nbd.2016.01.008_bb0090","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2967\/jnumed.114.146894","article-title":"Increased permeability-glycoprotein inhibition at the human blood\u2013brain barrier can be safely achieved by performing pet during peak plasma concentrations of tariquidar","volume":"56","author":"Kreisl","year":"2015","journal-title":"J. Nucl. Med."},{"issue":"12","key":"10.1016\/j.nbd.2016.01.008_bb0095","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1091\/mbc.E13-01-0042","article-title":"The E3 ubiquitin ligase mind bomb 1 ubiquitinates and promotes the degradation of survival of motor neuron protein","volume":"24","author":"Kwon","year":"2013","journal-title":"Mol. Biol. Cell"},{"issue":"18","key":"10.1016\/j.nbd.2016.01.008_bb0100","doi-asserted-by":"crossref","first-page":"3667","DOI":"10.1093\/hmg\/ddr288","article-title":"Increasing expression and decreasing degradation of smn ameliorate the spinal muscular atrophy phenotype in mice","volume":"20","author":"Kwon","year":"2011","journal-title":"Hum. Mol. Genet."},{"issue":"6","key":"10.1016\/j.nbd.2016.01.008_bb0105","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1093\/hmg\/ddi078","article-title":"Smndelta7, the major product of the centromeric survival motor neuron (Smn2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length Smn","volume":"14","author":"Le","year":"2005","journal-title":"Hum. Mol. Genet."},{"issue":"1","key":"10.1016\/j.nbd.2016.01.008_bb0110","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.nbd.2016.01.008_bb0115","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.exphem.2008.04.013","article-title":"Overexpression of the Psmb5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma\/leukemia cells derived from Jurkat line","volume":"36","author":"Lu","year":"2008","journal-title":"Exp. Hematol."},{"issue":"1 Pt 1","key":"10.1016\/j.nbd.2016.01.008_bb0120","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1111\/j.1751-553X.2009.01145.x","article-title":"The effects of proteasome inhibitor bortezomib on a P-gp positive leukemia cell line K562\/A02","volume":"32","author":"Lu","year":"2010","journal-title":"Int. J. Lab. Hematol."},{"issue":"7","key":"10.1016\/j.nbd.2016.01.008_bb0125","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.exphem.2009.04.001","article-title":"Different mutants of Psmb5 confer varying bortezomib resistance in T lymphoblastic lymphoma\/leukemia cells derived from the Jurkat cell line","volume":"37","author":"Lu","year":"2009","journal-title":"Exp. Hematol."},{"issue":"6","key":"10.1016\/j.nbd.2016.01.008_bb0130","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1086\/515465","article-title":"Identification of proximal spinal muscular atrophy carriers and patients by analysis of smnt and smnc gene copy number","volume":"60","author":"McAndrew","year":"1997","journal-title":"Am. J. Hum. Genet."},{"issue":"4","key":"10.1016\/j.nbd.2016.01.008_bb0135","first-page":"803","article-title":"The mechanism of cross-resistance to proteasome inhibitor bortezomib and overcoming resistance in Ewing's family tumor cells","volume":"31","author":"Nakamura","year":"2007","journal-title":"Int. J. Oncol."},{"issue":"5","key":"10.1016\/j.nbd.2016.01.008_bb0140","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1007\/s00280-013-2136-7","article-title":"The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias","volume":"71","author":"O'Connor","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"11","key":"10.1016\/j.nbd.2016.01.008_bb0145","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1038\/jcbfm.2012.126","article-title":"Drug transport across the blood\u2013brain barrier","volume":"32","author":"Pardridge","year":"2012","journal-title":"J. Cereb. Blood Flow Metab."},{"issue":"7","key":"10.1016\/j.nbd.2016.01.008_bb0150","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1073\/pnas.96.7.3900","article-title":"Choroid plexus epithelial expression of Mdr1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier","volume":"96","author":"Rao","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.nbd.2016.01.008_bb0155","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.vascn.2010.11.003","article-title":"Rapid detection of Abc transporter interaction: potential utility in pharmacology","volume":"63","author":"Robey","year":"2011","journal-title":"J. Pharmacol. Toxicol. Methods"},{"issue":"1","key":"10.1016\/j.nbd.2016.01.008_bb0160","first-page":"145","article-title":"Overexpression of the Atp-binding cassette half-transporter, Abcg2 (Mxr\/Bcrp\/Abcp1), in flavopiridol-resistant human breast cancer cells","volume":"7","author":"Robey","year":"2001","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.nbd.2016.01.008_bb0165","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.bbrc.2007.07.049","article-title":"Knockdown of Pgp resensitizes leukemic cells to proteasome inhibitors","volume":"361","author":"Rumpold","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.nbd.2016.01.008_bb0170","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3389\/fphar.2012.00046","article-title":"Barrier mechanisms in the developing brain","volume":"3","author":"Saunders","year":"2012","journal-title":"Front. Pharmacol."},{"issue":"4","key":"10.1016\/j.nbd.2016.01.008_bb0175","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/0092-8674(94)90212-7","article-title":"Disruption of the mouse Mdr1a P-glycoprotein gene leads to a deficiency in the blood\u2013brain barrier and to increased sensitivity to drugs","volume":"77","author":"Schinkel","year":"1994","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.nbd.2016.01.008_bb0180","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1172\/JCI118699","article-title":"P-glycoprotein in the blood\u2013brain barrier of mice influences the brain penetration and pharmacological activity of many drugs","volume":"97","author":"Schinkel","year":"1996","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.nbd.2016.01.008_bb0185","first-page":"152","article-title":"Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase ii in a human breast carcinoma Mcf7 cell line selected for etoposide resistance","volume":"54","author":"Schneider","year":"1994","journal-title":"Cancer Res."},{"issue":"51","key":"10.1016\/j.nbd.2016.01.008_bb9100","doi-asserted-by":"crossref","first-page":"40125","DOI":"10.1074\/jbc.M110.160606","article-title":"Nature of pharmacophore influences active site specificity of proteasome inhibitors","volume":"285","author":"Screen","year":"2010","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.nbd.2016.01.008_bb0190","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s12032-008-9107-6","article-title":"In vitro activity of bortezomib in cultures of patient tumour cells\u2014potential utility in haematological malignancies","volume":"26","author":"Wiberg","year":"2009","journal-title":"Med. Oncol."}],"container-title":["Neurobiology of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996116300079?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996116300079?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,16]],"date-time":"2018-09-16T03:55:29Z","timestamp":1537070129000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969996116300079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":40,"alternative-id":["S0969996116300079"],"URL":"https:\/\/doi.org\/10.1016\/j.nbd.2016.01.008","relation":{},"ISSN":["0969-9961"],"issn-type":[{"value":"0969-9961","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CNS uptake of bortezomib is enhanced by P-glycoprotein inhibition: implications for spinal muscular atrophy","name":"articletitle","label":"Article Title"},{"value":"Neurobiology of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nbd.2016.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}